Incidence, Risk Factors and Outcomes of Submacular Hemorrhage with Loss of Vision in Neovascular Age-Related Macular Degeneration in Daily Clinical P…

2022

A Pharmacoepidemiological study of intravitreal drug consumption in the first 12 months of treatment. The EPIdemiology and SAFEty collaboration

2017

Incidence, Risk Factors and Outcomes of Submacular Hemorrhage with Loss of Vision in Neovascular Age-Related Macular Degeneration in Daily Clinical P…

2023

To evaluate the proportion, baseline predictors, and outcomes of neovascular age-related macular degeneration (nAMD) patients treated with a high burden of vascular endothelial growth factor (VEGF) inhibitor intravitreal injections (IVT) at two years in routine clinical practice. European retrospective data analysis from a prospectively designed observational outcomes registry: the Fight Retinal Blindness! (FRB!) Project. Treatment-naïve eyes (one eye per patient) initiating VEGF inhibitors IVT from January 2017 to March 2020 with 24 months of follow-up, a minimum of 3 injections, and no gap between visits exceeding 365 days were tracked in the registry. We analyzed three treatment burden (…